Back to top
more

Brainstorm Cell Therapeutics (BCLI)

(Delayed Data from NSDQ)

$0.53 USD

0.53
265,201

0.00 (0.47%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $0.52 -0.01 (-2.71%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Brainstorm Cell Therapeutics Inc. [BCLI]

Reports for Purchase

Showing records 1 - 20 ( 66 total )

Company: Brainstorm Cell Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

08/16/2022

Daily Note

Pages: 4

Termination of Coverage

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Brainstorm Cell Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

05/25/2022

Company Report

Pages: 4

Neutral-Rated Reports Q1 Burning $5M a QTR, $22M in Cash, but Where is this Going?

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Brainstorm Cell Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

12/22/2021

Company Report

Pages: 4

Neutral-Rated Reports Q3 Our Comments are Unchanged: Does NurOwn Work?

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Brainstorm Cell Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for BCLI

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Brainstorm Cell Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

08/05/2021

Company Report

Pages: 4

Neutral-Rated - Reports the Quarter - Our Comments are Unchanged from the Prior QTR:Company has Cash, but Signal to Noise Ratio is High

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Brainstorm Cell Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

04/26/2021

Company Report

Pages: 4

Neutral-Rated Reports the Quarter - Company has Cash, but Signal to Noise Ratio is High

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Brainstorm Cell Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

03/24/2021

Company Report

Pages: 4

Neutral-Rated- Progressive Multiple Sclerosis?

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Brainstorm Cell Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

02/22/2021

Company Report

Pages: 5

Neutral-FDA Says You Haven''t Met the Threshold

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Brainstorm Cell Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

11/17/2020

Company Report

Pages: 6

Neutral - A High Placebo Response in ALS Causes a Lack of Significance Between the Active Arm 35% vs. Placebo 28%. Is There a Path Forward?

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Brainstorm Cell Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

10/22/2020

Company Report

Pages: 6

BUY -Brainstorm Secures Manufacturing for NurOwn

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Brainstorm Cell Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

10/16/2020

Company Report

Pages: 7

BUY - On Track in ALS For Data by Year''s End, Rolling our Valuation Forward - Raising Price Target from $14.00 to $25.00

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Brainstorm Cell Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

08/07/2020

Company Report

Pages: 6

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Brainstorm Cell Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

05/07/2020

Company Report

Pages: 7

BUY On Track in ALS For Data by Year''s End

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Brainstorm Cell Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

03/24/2020

Industry Report

Pages: 15

COVID-19 and Clinical Trials: A Combo That Doesn''t Mix?

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 50.00

Research Provided by a Third Party

Company: Brainstorm Cell Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

02/20/2020

Company Report

Pages: 6

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Brainstorm Cell Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

02/19/2020

Company Report

Pages: 7

Marching To Results - Maybe Approval - ALS

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Brainstorm Cell Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

02/12/2020

Company Report

Pages: 7

Regulatory Path in ALS is Now Defined

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Brainstorm Cell Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

11/21/2019

Company Report

Pages: 7

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Brainstorm Cell Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

11/20/2019

Company Report

Pages: 7

NurOwn Published in the Journal of Neurology

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Brainstorm Cell Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

10/15/2019

Company Report

Pages: 7

ALS Pivoatl Trial is now Fully Enrolled.

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party